+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Clinical Trials Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797970
The clinical trial market size attained a value of USD 46.7 Billion in 2022. The market is anticipated to grow at a CAGR of 5.40% during the forecast period of 2023-2031 to attain a value of nearly USD 75 billion by 2031.

Clinical Trial Market: Introduction

Clinical trials are research studies involving human participants, designed to evaluate the safety, efficacy, and optimal usage of medical interventions. These interventions can include drugs, medical devices, vaccines, diagnostic tools, surgical procedures, or behavioural therapies. Clinical trials play a crucial role in the development of new treatments and advancements in medical practice, as they provide evidence-based information on the safety and effectiveness of these interventions.

Clinical trials typically follow a structured process and are conducted in various phases, with each phase focusing on a specific aspect of the intervention. These phases range from Phase 0, which involves exploratory studies, to Phase 4, which includes post-marketing surveillance. The trials are conducted under strict ethical and regulatory guidelines to ensure the safety of participants and the validity of the results.

Applications of Clinical Trials:
  • Drug development: Clinical trials are an essential part of the drug development process, as they help determine the safety, efficacy, dosage, and potential side effects of new medications. Data collected from these trials is critical for regulatory approval and the eventual introduction of new drugs into the market
  • Medical devices: Clinical trials are also used to evaluate the safety and effectiveness of medical devices, such as implants, diagnostic tools, and surgical instruments. These studies provide insights into the performance of the device, possible risks, and overall benefits for patients
  • Treatment protocols: Clinical trials can help establish the most effective treatment protocols and guidelines for various medical conditions. By comparing different approaches, researchers can determine the best course of action for specific patient populations
  • Disease prevention: Clinical trials play a significant role in the development of preventive measures, such as vaccines or lifestyle interventions, to reduce the incidence of diseases and improve overall public health
  • Quality of life improvement: In addition to evaluating the direct effects of medical interventions, clinical trials often examine their impact on patients' quality of life. This information can help healthcare providers make informed decisions about treatment options and patient care
In summary, clinical trials are a fundamental aspect of medical research, providing valuable insights into the safety, efficacy, and optimal use of medical interventions. They play a crucial role in the development of new treatments, devices, and preventive measures, ultimately contributing to the advancement of medical practice and the improvement of patient outcomes.

Clinical Trial Market Segmentations

The market can be categorised into segments like design, phase, service type, therapy area, application, and region.

Market Breakup by Design

  • Treatment Studies
  • Randomised Control Trial
  • Adaptive Clinical Trail
  • Non- Randomised Control Trial
  • Observational Studies
  • Cohort Studies
  • Case Control Studies
  • Cross Section Study
  • Ecological Study
  • Others

Market Breakup by Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Market Breakup by Service Type

  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Bio-Analytical Testing Services
  • Cell Based Assay
  • Virology Testing
  • PK/PD Testing Services
  • Method Development, Optimization, Validation
  • Serology, Immunogenicity and Neutralizing Antibodies
  • Bio Marker Testing Service
  • Other Bioanalytical Testing Services
  • Clinical Trial Data Management Services
  • Clinical Trial Supply and Logistic Services
  • Medical Device Testing Services
  • Other Clinical Trial Services

Market Breakup by Therapy Area

  • Oncology
  • Infectious Disease
  • Neurology
  • Immunology
  • Cardiology
  • Genetic Disease
  • Women’s Health
  • Other Therapy Areas

Market Breakup by Application

  • Small Molecule
  • Vaccine
  • Cell and Gene Therapy
  • Other Applications

Clinical Trial Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Clinical Trial Market Scenario

The clinical trial market has been experiencing consistent growth, fuelled by various factors that contribute to its expansion and evolution. These factors include an increase in the number of chronic diseases, advancements in technology, and a greater focus on personalized medicine.

The clinical trial market has experienced notable growth due to key drivers and developments, such as the rising prevalence of chronic diseases necessitating innovative treatments, technological advancements that streamline trial processes and enable decentralized trials, and the focus on personalized medicine for targeted therapies. Additionally, supportive regulatory policies expedite approval processes for ground-breaking treatments, particularly in areas with unmet medical needs or rare diseases. The expansion of clinical research into emerging markets, with their large patient populations and lower operational costs, has also significantly contributed to the growth and evolution of the clinical trial market.

In conclusion, the clinical trial market has been growing steadily due to a combination of factors, including the rising prevalence of chronic diseases, technological advancements, and the focus on personalized medicine. The future outlook for the market remains promising, with ongoing innovations and developments in medical research expected to drive further growth and expansion in the coming years.

Key Players in the Global Clinical Trial Market

The report gives an in-depth analysis of the key players involved in the clinical trial market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • IQVIA
  • PAREXEL International Corporation
  • Charles River Laboratory
  • ICON Plc
  • Financial Analysis
  • Syneos Health
  • Labcorp Drug Development (COVANCE)
  • Wuxi Apptec
  • Charles River Laboratories
  • PPD Inc
  • ICON Plc
  • Medpace Holdings Inc
  • Acm Global Laboratories
  • Advanced Clinical
  • SGS
  • PSI CRO AG
  • Bio Agile Therapeutics

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Clinical Trial Market Overview
3.1 Global Clinical Trial Market Historical Value (2016-2022)
3.2 Global Clinical Trial Market Forecast Value (2023-2031)
4 Global Clinical Trial Market Landscape
4.1 Global Clinical Trial Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Clinical Trial Product Landscape
4.2.1 Analysis by Service Type
4.2.2 Analysis by Design
4.2.3 Analysis by Therapy Area
5 Global Clinical Trial Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Clinical Trial Market Segmentation
6.1 Global Clinical Trial Market by Design
6.1.1 Market Overview
6.1.2 Treatment Studies
6.1.2.1 Randomised Control Trial
6.1.2.2 Adaptive Clinical Trail
6.1.2.3 Non- Randomised Control Trial
6.1.3 Observational Studies
6.1.3.1 Cohort Studies
6.1.3.2 Case Control Studies
6.1.3.3 Cross Section Study
6.1.3.4 Ecological Study
6.1.3.5 Others
6.2 Global Clinical Trial Market by Phase
6.2.1 Market Overview
6.2.2 Phase I
6.2.3 Phase II
6.2.4 Phase III
6.2.5 Phase IV
6.3 Global Clinical Trial Market by Service Type
6.3.1 Market Overview
6.3.2 Site Identification
6.3.3 Patient Recruitment
6.3.4 Laboratory Services
6.3.5 Analytical Testing Services
6.3.6 Bio-Analytical Testing Services
6.3.6.1 Cell Based Assay
6.3.6.2 Virology Testing
6.3.6.3 PK/PD Testing Services
6.3.6.4 Method Development, Optimization, Validation
6.3.6.5 Serology, Immunogenicity & Neutralizing Antibodies
6.3.6.6 Bio Marker Testing Service
6.3.6.7 Other Bioanalytical Testing Services
6.3.7 Clinical Trial Data Management Services
6.3.8 Clinical Trial Supply and Logistic Services
6.3.9 Medical Device Testing Services
6.3.10 Other Clinical Trial Services
6.4 Global Clinical Trial Market by Therapy Area
6.4.1 Market Overview
6.4.2 Oncology
6.4.3 Infectious Disease
6.4.4 Neurology
6.4.5 Immunology
6.4.6 Cardiology
6.4.7 Genetic Disease
6.4.8 Women’s Health
6.4.9 Other Therapy Areas
6.5 Global Clinical Trial Market by Application
6.5.1 Market Overview
6.5.2 Small Molecule
6.5.3 Vaccine
6.5.4 Cell & Gene Therapy
6.5.5 Other Applications
6.6 Global Clinical Trial Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Clinical Trial Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Clinical Trial Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Clinical Trial Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Clinical Trial Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Clinical Trial Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 IQVIA
17.1.1 Financial Analysis
17.1.2 Service Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 PAREXEL International Corporation
17.2.1 Financial Analysis
17.2.2 Service Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Charles River Laboratory
17.3.1 Financial Analysis
17.3.2 Service Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 ICON Plc
17.4.1 Financial Analysis
17.4.2 Service Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Syneos Health
17.5.1 Financial Analysis
17.5.2 Service Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Labcorp Drug Development (COVANCE)
17.6.1 Financial Analysis
17.6.2 Service Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Wuxi Apptec
17.7.1 Financial Analysis
17.7.2 Service Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Charles River Laboratories
17.8.1 Financial Analysis
17.8.2 Service Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 PPD Inc
17.9.1 Financial Analysis
17.9.2 Service Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 ICON Plc
17.10.1 Financial Analysis
17.10.2 Service Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Medpace Holdings Inc
17.11.1 Financial Analysis
17.11.2 Service Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Acm Global Laboratories
17.12.1 Financial Analysis
17.12.2 Service Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Advanced Clinical
17.13.1 Financial Analysis
17.13.2 Service Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 SGS
17.14.1 Financial Analysis
17.14.2 Service Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 PSI CRO AG
17.15.1 Financial Analysis
17.15.2 Service Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Bio Agile Therapeutics
17.16.1 Financial Analysis
17.16.2 Service Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
18 Global Clinical Trial Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Iqvia
  • Parexel International Corporation
  • Charles River Laboratory
  • Icon plc
  • Syneos Health
  • Labcorp Drug Development (Covance)
  • Wuxi Apptec
  • Charles River Laboratories
  • Ppd Inc
  • Icon plc
  • Medpace Holdings Inc
  • Acm Global Laboratories

Methodology

Loading
LOADING...

Table Information